StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)

Close on Nov 17, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aytu BioPharma's operating cash flow for the twelve months ending Jun 30, 2026 was $3.28M. For fiscal 2026 it was $3.28M. The highest annual figure on record is $3.28M in fiscal 2026.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026$3.28M–
FY2025Jun 30, 2025-$1.94M–
FY2024Jun 30, 2024-$1.39M–
FY2023Jun 30, 2023-$5.13M–
FY2022Jun 30, 2022-$28.82M–
FY2021Jun 30, 2021-$25.96M–
FY2020Jun 30, 2020-$28.37M–
FY2019Jun 30, 2019-$13.83M–
FY2018Jun 30, 2018-$15.94M–
FY2017Jun 30, 2017-$13.83M–
FY2016Jun 30, 2016-$10.66M–
FY2015Jun 30, 2015-$6.63M–
FY2013Aug 31, 2013-$37.70K–
FY2012Aug 31, 2012-$37.85K–
FY2011Aug 31, 2011-$64.82K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$4.41M+57.2%
Q3 FY2026CQ1 2026Mar 31, 2026-$4.18M–
Q2 FY2026CQ4 2025Dec 31, 2025$3.68M+26.5%
Q1 FY2026CQ3 2025Sep 30, 2025-$618.00K–
Q4 FY2025CQ2 2025Jun 30, 2025$2.80M–
Q3 FY2025CQ1 2025Mar 31, 2025-$6.46M–
Q2 FY2025CQ4 2024Dec 31, 2024$2.91M–
Q1 FY2025CQ3 2024Sep 30, 2024-$1.19M–
Q4 FY2024CQ2 2024Jun 30, 2024-$788.00K-108.4%
Q3 FY2024CQ1 2024Mar 31, 2024-$254.00K–
Q2 FY2024CQ4 2023Dec 31, 2023-$135.00K–
Q1 FY2024CQ3 2023Sep 30, 2023-$211.00K–
Q4 FY2023CQ2 2023Jun 30, 2023$9.37M–
Q3 FY2023CQ1 2023Mar 31, 2023-$2.91M–
Q2 FY2023CQ4 2022Dec 31, 2022-$2.44M–
Q1 FY2023CQ3 2022Sep 30, 2022-$9.15M–
Q4 FY2022CQ2 2022Jun 30, 2022-$7.10M–
Q3 FY2022CQ1 2022Mar 31, 2022-$9.12M-146.3%
Q2 FY2022CQ4 2021Dec 31, 2021-$8.82M–
Q1 FY2022CQ3 2021Sep 30, 2021-$3.79M–
Q4 FY2021CQ2 2021Jun 30, 2021-$6.28M–
Q3 FY2021CQ1 2021Mar 31, 2021$19.70M-4.4%
Q2 FY2021CQ4 2020Dec 31, 2020-$2.92M–
Q1 FY2021CQ3 2020Sep 30, 2020-$7.98M–
Q4 FY2020CQ2 2020Jun 30, 2020-$7.76M–
Q3 FY2020CQ1 2020Mar 31, 2020$20.60M–
Q2 FY2020CQ4 2019Dec 31, 2019-$6.10M–
Q1 FY2020CQ3 2019Sep 30, 2019-$2.99M–
Q4 FY2019CQ2 2019Jun 30, 2019-$3.47M–
Q3 FY2019CQ1 2019Mar 31, 2019-$3.31M–
Q2 FY2019CQ4 2018Dec 31, 2018-$4.30M–
Q1 FY2019CQ3 2018Sep 30, 2018-$2.74M–
Q4 FY2018CQ2 2018Jun 30, 2018-$4.54M–
Q3 FY2018CQ1 2018Mar 31, 2018-$4.08M–
Q2 FY2018CQ4 2017Dec 31, 2017-$3.10M–
Q1 FY2018CQ3 2017Sep 30, 2017-$4.22M–
Q4 FY2017CQ2 2017Jun 30, 2017-$3.27M–
Q3 FY2017CQ1 2017Mar 31, 2017-$2.39M–
Q2 FY2017CQ4 2016Dec 31, 2016-$2.84M–
Q1 FY2017CQ3 2016Sep 30, 2016-$5.33M–

More Aytu BioPharma figures

See a number that looks wrong?